In the Phase III IMpower010 trial, adjuvant Tecentriq reduced the risk of disease recurrence or death by 57% in people with PD-L1 high resected Stage II-III NSCLC, compared with best supportive careTecentriq
SOUTH SAN FRANCISCO (dpa-AFX) - Roche Holding AG's (RHHBY) blockbuster drug Tecentriq has been approved by the European Commission for yet another lung cancer indication - this time, as an adjuvant
First study conducted in the adjuvant setting with a combination of BRAF and MEK inhibitors in high-risk stage II BRAF V600E/K-mutant cutaneous melanomaA global partnership between EORTC and